For example, seven patients, who were treated with etanercept, adalimumab, or rituximab, improved and had SAA suppression after tocilizumab therapy, and one patient, who was treated with a TNF inhibitor and tocilizumab, achieved remission with abatacept.[30,42] This suggests that biologic agents need to be replaced to suppress the progression of AA amyloidosis secondary to RA, depending on the patient. This evidence concerns the gene SAA1 and AA amyloidosis.